Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy

Cells(2022)10.3390/cells11233717Source: DataRank Database

Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy is a research paper published in Cells (2022). On theSindex it has a DataRank of 0. It has been cited 42 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access42 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 3.13)OA: goldTopics (35)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Yoshimi Endo Greer ORCID,Jennifer Dine ORCID,Stanley Lipkowitz ORCID,Manjari Kundu ORCID

Live enrichment

PubMed:36496977 PMC:PMC9739296 OpenAlex:https://openalex.org/W4309588142

National Institutes of Health

Grant: ZIA SC 007263

National Institutes of Health

Grant: 1Z01SC007263-13

Molecular Control of Growth, Differentiation, and Death

FWCI

3.13

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2073-4409/11/23/3717/pdf?version=1669166143

publisherhttps://www.mdpi.com/2073-4409/11/23/3717/pdf?version=1669166143

publisherhttps://www.mdpi.com/2073-4409/11/23/3717/pdf

journalhttps://doi.org/10.3390/cells11233717

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36496977

Fields of Study

Cell death mechanisms and regulationRNA Interference and Gene DeliveryNF-κB Signaling Pathways0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

HumansApoptosisCell Line, TumorReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing LigandTriple Negative Breast Neoplasms

Keywords

Triple-negative breast cancerMedicineBreast cancerCancerClinical trialCancer researchTumor necrosis factor alphaApoptosisOncologyBioinformaticsInternal medicineBiologyImmunomodulationTRAILDeath ReceptorsQH573-671Triple Negative Breast NeoplasmsReviewTNF-Related Apoptosis-Inducing LigandReceptors, TNF-Related Apoptosis-Inducing LigandCell Line, TumorHumansCytology

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26085119.v1figshare

Additional file 1 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26085119figshare

Additional file 2 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26085182figshare

Additional file 3 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26737767.v1figshare

Additional file 3 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26737767figshare

Additional file 4 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26737770.v1figshare

Additional file 4 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26737770figshare

Additional file 5 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26737773.v1figshare

Additional file 5 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26737773figshare

Additional file 6 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26737776.v1figshare

Additional file 6 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26737776figshare

Additional file 7 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26737779.v1figshare

Additional file 7 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26737779figshare

Additional file 2 of Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia

10.6084/m9.figshare.26085182.v1figshare